Literature DB >> 16203278

p63/AMACR antibody cocktail restaining of prostate needle biopsy tissues after transfer to charged slides: a viable approach in the diagnosis of small atypical foci that are lost on block sectioning.

Omar Hameed1, Peter A Humphrey.   

Abstract

We assessed the utility of using a p63/a-methylacyl-coenzyme-A racemase (AMACR) antibody cocktail on destained H&amp;E-stained sections. We transferred 61 stored (7-11 months old) and 10 recent (<1 month old) H&amp;E-stained sections of prostate needle biopsy tissues to charged slides and subsequently stained them with a p63/AMACR immunohistochemical antibody cocktail. The AMACR and p63 staining intensities were compared with those obtained with the same antibody cocktail performed on sections recut directly from the paraffin block. Transfer of sections and subsequent immunohistochemical staining was successful in 69 (97%) of 71 cases. For stored cases, there were similar AMACR and p63 staining intensities in destained and recut sections in 55 (90%) and 11 (18%) of 61 cases, respectively. In recent sections, AMACR and p63 staining intensities were almost identical by both methods. We conclude that p63/AMACR cocktail immunostaining of destained H&amp;E-stained sections is a viable approach in the workup of small "suspicious" foci in recently sectioned prostate needle biopsy tissues. This approach is best used when 2 or more H&amp;E-stained sections harbor the suspicious focus, as we always recommended preservation of at least 1 H&amp;E-stained section.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16203278     DOI: 10.1309/JXK1-BVAT-GBVN-Q9J9

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

Review 1.  Diagnosis of adenocarcinoma in prostate needle biopsy tissue.

Authors:  P A Humphrey
Journal:  J Clin Pathol       Date:  2007-01       Impact factor: 3.411

2.  p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.

Authors:  Rubeta N Matin; Anissa Chikh; Stephanie Law Pak Chong; David Mesher; Manuela Graf; Paolo Sanza'; Valentina Senatore; Maria Scatolini; Francesca Moretti; Irene M Leigh; Charlotte M Proby; Antonio Costanzo; Giovanna Chiorino; Rino Cerio; Catherine A Harwood; Daniele Bergamaschi
Journal:  J Exp Med       Date:  2013-02-18       Impact factor: 14.307

3.  Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer.

Authors:  K A Landers; H Samaratunga; L Teng; M Buck; M J Burger; B Scells; M F Lavin; R A Gardiner
Journal:  Br J Cancer       Date:  2008-07-22       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.